
Ofer Talmor
AlephBot is developing a new paradigm in healthcare, the procedure monitor.
The solution helps medical teams maximize treatment efficiency during and after medical procedures (e.g., resuscitation, labor, general anesthesia). It provides the team members with valuable real-time information that is adaptive to their actions and to the procedure’s stage, even if they are under pressure or can’t recall procedure steps by heart. AlephBot also automatically documents the medical procedure, which serves for both medical education and medico-legal purposes.
** AlephBot uniqueness **
We capture the human perspective of a procedure by analyzing the relevant info from the on-going structural medical conversation. We add this layer to the data collected from other sources.
Therefore, we gain higher accuracy of the analyzed medical situation, which enables us to identify the procedure stage and provide meaningful info, in real-time.
** Status **
AlephBot is developing its core technology. The company, pre-seed funded, was selected to the DRIVE accelerator at the Technion (Israel institute of Technology), and received grants from the Israel Innovation Authority.
AlephBot cooperates with big and small hospitals from day one. This serves our intention to increase treatment efficiency both in mega-hospitals in big cities and in smaller ones in the periphery and rural areas.
AlephBot is active in its target markets (Germany, France, Italy and the US) and won several national and international (France, Germany, Denmark) events and competitions. The company is still not active in China - an opportunity!
** Next steps **
We are currently looking for seed investment to finalize our core technology development and bring the product to clinical trial stage in two years. Sales are planned in three years, post regulation clearance.

AlephBot
CEO and co-founder
Jason Tang
• 岸迈生物科技有限公司是一家总部位于上海的生物制药研发公司。公司基于自主研发的FIT-Ig®双特异性抗体平台技术,聚焦于肿瘤IO领域的创新药品开发。公司的先锋产品EMB-01是一种基于FIT-Ig®平台的双特异性抗体,针对EGFR和c-MET靶点,目前正在进行针对实体瘤的全球I/II期临床试验。岸迈生物的目标是尽可能广泛地将其FIT-Ig®技术商业化,并最大限度地拓展基于该平台的新药开发。更多信息,请访问公司官网www.epimab.com。

EpimAb Biotherapeutics
BD head of ChinaRichard Tao
Shanghai Fenglin Biomedical Development Co. Ltd
Mr / Project Manager
Kun Tao
As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.
Mybiogate Inc.
Lu Tian
The company is a national key high-tech enterprise, with a national enterprise technology center, post-doctoral research station, provincial key enterprise research institute, provincial academician expert workstation, provincial high-tech enterprise R & D center, and Shanghai Research Institute in Shanghai Zhangjiang Hi-Tech Park.
Jingxin Pharmaceutical adheres to the mission of meticulously guarding health and is committed to becoming a front runner in neurological and cardiovascular therapy areas in China.
No. 70 pharmaceutical companies in China.
Shanghai Jingxin Biology&Pharmaceutical Co,.LTD
Project ManagerJessie Tong
Santen Pharmaceutical Co., Ltd. (参天製薬株式会社), is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries.
We are looking for investment and licensing opportunites in the ophthalmology field.